FEMASYS INC
FEMYNASDAQTrading Snapshot
- Day Range
- $1.38 – $1.44
- 52-Week Range
- $1.32 – $22.20
- Volume (shares)
- 63,420
- Avg Volume (shares)
- —
- Shares Outstanding
- 8.4M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $331,827
- P/E Ratio
- -0.3
- P/S Ratio
- 5.1x
- EPS (TTM)
- $-3.66
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +73.4%
FEMASYS INC
FEMY
StockOtter · stockotter.spaceAbout FEMASYS INC
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients First in a planned network of specialty pharmacy partnerships provides m
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- -- Twelve academic and private clinical sites across
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.
Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control solutions. FEMY's $30M PIPE recapitalization ties full funding to commercial traction; current market c
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standa
Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY)
Femasys (NASDAQ: FEMY - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their ris
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care
-- Leading multi-site OB/GYN health practice to implement FemVue ® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasy